Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05835011 · ClinicalTrials.gov registry record · Phase 2
A Study of Oral Decitabine/Cedazuridine in Combination With Magrolimab in Participants With Intermediate- to Very High-Risk Myelodysplastic Syndromes (MDS)
A Phase 2 study, sponsored by Astex Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT05835011 is a Phase 2 study that was terminated before completion, run by Astex Pharmaceuticals. The registered enrollment target is 2 participants.
The verdict
NCT05835011, a Phase 2 study, was terminated before completion, sponsored by Astex Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
The primary purpose of the study is to evaluate the preliminary safety and efficacy of oral decitabine/cedazuridine in combination with magrolimab.
Interventions
- DRUG Magrolimab
- DRUG Decitabine/Cedazuridine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2023-06-27 |
| Est. Completion | 2023-08-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05835011
The ClinicalTrials.gov registry entry for NCT05835011 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astex Pharmaceuticals, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Magrolimab is the first listed.
NCT05835011 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05835011 about?
NCT05835011 is a clinical study titled "A Study of Oral Decitabine/Cedazuridine in Combination With Magrolimab in Participants With Intermediate- to Very High-Risk Myelodysplastic Syndromes (MDS)". The primary purpose of the study is to evaluate the preliminary safety and efficacy of oral decitabine/cedazuridine in combination with magrolimab.
What is the current status of trial NCT05835011?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2023-06-27. Estimated completion is 2023-08-21.
What interventions are being tested in trial NCT05835011?
The interventions under investigation include: Magrolimab (DRUG), Decitabine/Cedazuridine (DRUG).
Who is sponsoring clinical trial NCT05835011?
This trial is sponsored by Astex Pharmaceuticals, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.